MedTrace Logo

Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients

NCT04393675 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-02-10

Study results available
· View outcomes & findings →

Summary

A Randomized, Double Blind, Placebo-Controlled study to assess the Safety, Local Tolerance, and Pharmacokinetics of LT5001 drug product in Hemodialysis Patients with Uremic Pruritus

Conditions

  • Uremic Pruritus

Interventions

DRUG

LT5001

LT5001 is administered twice daily.

DRUG

Placebo

LT5001 is administered twice daily.

Sponsors & Collaborators

  • Lumosa Therapeutics Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • June Kuo · Lumosa Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-14
Primary Completion
2022-09-15
Completion
2022-09-15

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04393675 on ClinicalTrials.gov